Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 361-365

  García Cruz, Eduard ^a   Huguet, Jorge ^a   Piqueras, Marta ^a   Márquez, Meritxell Pérez ^a   Peri, Lluís ^a   Izquierdo, Laura ^a   Franco, Agustín ^a   Álvarez Vijande, Ricardo ^a   Ribal, María José ^a   Alcaraz, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Hypogonadism; Prostate biopsy; Prostate cancer; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DIGITAL RECTAL EXAMINATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; ORGAN SIZE; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; BIOPSY, NEEDLE; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84861645917     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0741-9     Document Type: Article

References (24)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2010) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2010 Oct 28.
2. Huggins C, Hodges CV (1941) Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
3. Huggins C, Stevens RE (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43: 705-714.
4. Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55(2): 310-320.
5. Gray A, Feldman HA, McKinlay JB, Longcope C (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 73(5): 1016-1025.
6. Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26(6): 833-876. Epub 2005 May 18.
7. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47(1): 52-58.
8. Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20(6): 605-608.
9. Hoffman MA, DeWolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163(3): 824-827.
10. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003) Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169(5): 1670-1675.
11. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM (2005) Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174(6): 2178-2180.
12. Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M (2008) Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 80(2): 134-140.
13. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16): 1118-1126.
14. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M (2004) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108(3): 418-424.
15. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60(11): 1451-1457.
16. Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350(5): 482-492.
17. Morgentaler A, Rhoden EL (2006) Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4. 0 ng/mL or less. Urology 68(6): 1263-1267.
18. Morgentaler A (2007) Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 52(3): 623-625.
19. Morgentaler A (2009) Rapidly shifting concepts regarding androgens and prostate cancer. Sci World J 9: 685-690.
20. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) Investigation, treatment, and monitoring of late- onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 55: 121-130.
21. Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM (2010) Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int 105(4): 481-484. Epub 2009 Aug 13.
22. Roddam A, Allen NE, Appleby P, Key TJ (2010) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. JNCI J Natl Cancer Inst 100: 170-183.
23. Morgentaler A, Bruning CO, De Wolf WC (1996) Occult prostate cancer in men with low serum testosterone levels. JAMA 276(23): 1904-1906.
24. Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41(6): 834-845.